Metabolic
Retatrutide
Still in trials, not available to buy or be prescribed anywhere yet. It works on three fronts at once: appetite, blood sugar, and directly burning fat. Early results are some of the strongest seen in this drug class, but 'not approved anywhere' is still the honest current status.
Investigational triple . Human efficacy evidence is now substantial, including positive pivotal phase 3 results, but regulatory approval has not yet been granted.
How well studied
Tier Guide: A = Well studied, B = Some good studies, C = Early evidence & D = Barely studied
Backed by large human trials, so we have solid data on how it works and what it does.
UK status
How you could legitimately come across it here, if at all
This is still being studied in clinical trials and is not authorised anywhere, so there is no routine legal route to it in the UK.
Evidence strength and UK regulatory status answer different questions.
Heightened caution: this compound carries unresolved regulatory, safety or supply-chain concerns in the UK. Nothing here is a recommendation to use it.
Overview
How it works
Three separate hunger-and-metabolism switches get hit at once, more than any other weight-loss drug, which is why the results are so strong.
Hits three metabolic switches at once: reduces appetite, increases fullness signalling, and directly increases fat-cell energy burning via the pathway.
Reported benefits
- Large weight reductions have been demonstrated in randomised phase 2 trials and reported in pivotal phase 3 topline results
- Improves multiple cardiometabolic measures in obesity trials
Who it's typically used for
Timeline to results
Safety & UK access
Dosage
Phase 2 trial ladder: 1 mg escalating towards 12 mg weekly over twelve weeks, under clinical supervision with monitoring. That is a research protocol run by investigators, not a self-administration schedule, and retatrutide is not licensed anywhere.
Side effects
- Nauseavery common in the phase 2 obesity trial, dose-dependent and mostly during escalation
- Diarrhoeavery common in that trial
- Constipationcommon in that trial
- Vomitingcommon in that trial and the main reason participants stopped
- Skin tingling (dysesthesia)reported in that trial, more often at higher doses
- Higher heart ratereported in that trial
Getting it in the UK
This is still being studied in clinical trials and is not authorised anywhere, so there is no routine legal route to it in the UK.
Where it turns up
- Clinical trials only
- Not routinely available in the UK
- Unregulated online market
Still being tested in clinical trials and not authorised anywhere yet, so there is no routine legal UK supply. Anything sold online sits outside that system.
Not approved anywhere, so there is no legal UK supply chain. Earliest realistic approval 2027
MHRA: the UK regulator that assesses whether a medicine is safe and works before it can be authorised for use here. Something not being MHRA-licensed does not automatically mean it is illegal, and it does not mean it is safe.
This is background information about UK regulation, not advice about what you can or should obtain.
Evidence & sources
Why this rating?
The A to D rating shown above comes from our earlier editorial review and is still waiting to be migrated into the structured review record below. That is a gap in our record-keeping, not a sign the rating is wrong.
Evidence fingerprint
No route and indication scope has been published for this profile yet, so no fingerprint is shown.
Sources
Structured source audit not yet published for this profile. The references behind this page are being catalogued one compound at a time, and this one has not been through that process yet.
Content freshness
- Last reviewed
- 24 Sept 2026
- Regulatory status last checked
- 21 Aug 2026